002399 2022-022

2021

2022 4 18

2021 2022 85

1 2021 63.65 19.38%

2.41 76.49%

0.9 84.78%

-662.93 117.78%

1

2

3 26.38 73.2%

4

1

	546.26	0.09%	238.47	0.04%	307.79	0.04%
	22,226.29	3.49%	132,783.62	24.90%	110,557.33	-21.41%
	-1,112.05	-0.17%	30,620.45	5.74%	-31,732.50	-5.92%
	23,338.34	3.67%	102,163.18	19.16%	-78,824.84	-15.49%

2

	2021	2020		
	655,706.05	493,056.28	162,649.77	32.99%
	36,527.41	19,908.70	16,618.70	83.47%
	5,216.47	12,164.85	-6,948.38	-57.12%
	697,449.92	525,129.83	172,320.09	32.81%
	538,910.32	364,215.74	174,694.59	47.96%
	67,910.74	62,625.58	5,285.16	8.44%
	23,592.98	28,960.65	-5,367.68	-18.53%
	67,698.82	65,599.51	2,099.32	3.20%
	698,112.86	521,401.47	176,711.38	33.89%
	-662.93	3,728.36	-4,391.29	-117.78%

3

	2021	2020		
	23,338.34	102,163.18	-78,824.83	-77.16%
	25,801.00	5,587.87	20,213.13	361.73%

/	14,177.15	-34,674.77	48,851.92	-140.89%
	42,390.05	17,251.97	25,138.08	145.71%
	-224.17	-9,656.01	9,431.84	-97.68%
/	-662.93	3,728.36	-4,391.29	-117.78%

4

	2021	2020		
	24,078.76	102,420.98	-78,342.23	-76.49%
	9,011.21	59,200.75	-50,189.54	-84.78%
	-662.93	3,728.36	-4,391.29	-117.78%

2021 63.65 2020 53.32 10.33 19.38%

2021 2.41 2020 10.24 7.83

76.49%

1 , 203,303 2020 208,780

31.94% 2020 39.16%

2 9.84

1 2021 22,309 2020

Resverlogix Corp. RVX

, RVX

18,614 2020 3,695

2020

2

1.20 2020

2.31 3.51

3

0.64

2020 4.31

19.38% 76.49%

9,011.21 2020

59,200.75 50,189.54 84.78%

1 , 203,303 2020 208,780

5,477 31.94% 2020

39.16%

2 2021 22,309 2020

RVX

RVX

18,614 2020 3,695

2020

3

1.20 2020

2.31 3.51

19.38%

84.78%

2021 662.93 ,2020 3,728.36

4,391.29 117.78%

1 , 16.26

32.99%

2 1.66 83.47%

10.06 20.96%

3 17.47 47.96%

10.88

2021

2021

2021

15.20 8.40

1.84

2021

2

	2021		2020		
	272,201.34	42.76%	270,117.58	50.66%	0.77%
	238,939.65	37.54%	227,725.26	42.71%	4.92%
	33,261.69	5.22%	42,392.32	7.95%	-21.54%
	263,816.91	41.45%	152,319.43	28.57%	73.20%
	248,187.86	38.99%	148,953.15	27.94%	71.45%
	15,629.05	2.46%	3,366.29	0.63%	150.76%
CDMO	81,310.36	12.77%	79,738.70	14.95%	1.97%
	70,117.99	11.02%	57,659.92	10.81%	21.61%
	11,192.38	1.76%	22,078.78	4.14%	-49.31%
	19,189.14	3.01%	31,031.77	5.82%	-38.16%

2021 1.3

49.26% 59.27%

2021 1300

2021

8

300% 299%

60 40

2021

2021 400

16.16% , Prolongin

4

2021 662.93 ,2020 3,728.36

4,391.29 117.78%

2021

2021

2021

83,967.18 61,011.34

2021

2021

1.

2. CDMO

3.

4. CDMO

i CDMO

ii CDMO

5.

6. CDMO

7.

2021

1.

2021

1.

2.

2021

2021

13

2 29.44 18.86

20 19 8.7 7

2.02 2020 H

35.38 2021 24.27

0% 0% 10%

1

2

3

4 14.14

1

API

	2021.12.31	2020.12.31
	29.44	27.12
	191.08	190.26
	47.91	36.13
	27.93	37.24
	75.85	73.37
	39.69%	38.56%
	-0.07	0.37

2.53

TPG ORI

Kymab Group Limited 1.09

7.04

36.94

37.31

	2021.12.31	2020.12.31
	29.44	27.12
	9.40	8.21
	38.84	35.33

2021 12 31 38.84 H

24.27 14.57

4.57

2021 38.84 2020 9.93% 29.44

9.40 2020 14.78 3

14.53

14.57

	2021.12.31	2020.12.31
	188,628.47	185,976.29
	138,803.78	153,362.35
	86,223.22	155,223.32
	141,363.54	64,781.43
	29.79	24.19
	376.95	356.97
	555,425.75	559,724.55

2021 39.69% 2020 1.13% 2021

2021 2020

29.07% 29.42% 2021 2020

3

18. 86 1.43%

13.88 9.49%

8.62 44.45% 19

2022 3 22

19

69.93%

29.32 1.55

224.77% 1.26

2

19 2019 4 19 7

4.00 1.33 1.38 19

20 2020 2 26 8.7

2020 7 8 220,094,500 H

35.38 H

111,107.5 103,441.32

7,666.91 H

( )

, Cytovance Biologics Inc

3

	( )		(1)		(2)	(3) (2)/(1)	
		106,148.62	106,148.62	0	103,441.31	97.45%	12

( )

106,148.62

	7.48
	0.32
	14.14

14.14

18.63%

2021 2020 7.66

118.22% 19

1 19

2 2022 3 31 31

3

3 2021 47.08 31.68

48.59% 2019 23.74

1

2

3

4

5

1

	30-45
	7-15
	5-15

	19-33
	30-52
	3-30

	7-14
	7-14
	7-14

2021 2020

	2021		2020			
	171,144	36.36%	87,174	27.51%	83,970	96.32%
	94,182	20.01%	75,788	23.92%	18,394	24.27%
	202,285	42.97%	152,043	47.99%	50,242	33.04%
	1,629	0.35%	1,592	0.50%	37	2.32%
	1,515	0.32%	228	0.07%	1,287	564.47%
	470,755	100.00%	316,825	100.00%	153,930	48.59%

2020 2019

1 2019

2020 2021 46.25 53.32 63.65

2020 2019 15.30% 2021 2020 19.38%

2 2021

2021

2021

2021

3

2

2021 96.32%

2020 27.51% 2021 36.36% 2020

23.92% 47.99% 2021 20.01% 42.97%

2021 2020

		2021	2020	
603707		0.34	0.31	

3

A	2021 12			100%		
B	2021 12			100%		
	2021 12			100%		
	2021 12			100%		
	2022 1			100%		

	44,950.10	4,092.82	-	-	-	-	-	-	-
	63,493.19	6,098.30	-	-	655.85		-	10.75%	-
	1,596.58	14.05	17.87	-	-	-	-	-	-
	1,514.88	-	0.62	-	-	-	-	-	-
	447,526.05	28,266.37	2,950.59	0.74	7,524.45	462.96	0.00%	26.62%	15.69%

		2021	2020
603707		0.41%	0.82%
300255		0.00%	0.00%
002550		0.09%	0.99%

2021 1.67% 2020 3.03% 1.36%

0.00%-0.99%

	4.77%
	-1.11%
	4.31%

2021 2020 10.88 33.53% 2021 2020

15.39 48.59%

3 1 2021

2021

2021

1.

2.

3.

4.

5.

6.

7.

8.

2021

2021

30

4 2021 2.46 2020 1.46

49.9% 10.06%

2.43%

1

2

1

1

H1710

1

III

603707		
300255		I

1´

002550

2

III

3

2021 24,582.47 2020 16,399.44

49.9% 1

2 AR-301 3

	2021	2020		
	9,347.84	4,633.20	4,714.64	101.8%
AR-301	2,472.54	398.37	2,074.17	520.7%
	3,323.06	2,266.91	1,056.15	46.6%
	9,439.03	9,100.96	338.07	3.7%
	24,582.47	16,399.44	8,183.03	49.9%

1

2021

2021 FDA

2021

8

300% 299%

60 40 2021

26.89% 53.60

26.38 73.2% 41.45% 1.8

72.60%

2 AR-301 CRO

AR-301 2020 2021

AR-301 20 12 6

21 1-4 10 16

21 2021 GCP

CRO

CMC 2021

SMO

2021

global Sponsor

2021

2020

3 H1710

Heparan Sulfate,HS

H1710 H1710

IND

2023 2021

IND

cGMP

4 2

III

4 3 2

2021

		2021	2021	
603707	*	27,566	5,471	20%
300255		21,952	6,889	31%
002550		8,424	1,305	15%
002399		24,582	2,473	10%

2020

		2020	2020	
603707		22,305	3,552	16%
300255		16,963	4,208	25%
002550		7,669	755	10%
002399		16,399	399	2%

2021 10% 31%

2020 2% 10%-25%

III

III AR-301 2020 2021

2021

2021

1.

2.

3.

4.

5.

6.

7.

8.

2021

2021

38

5 2021 11.46 1.2

2.23 4.75 1.06

9.96

1

2

3

4

5

1

1

2021 -22

2 Aridis

Pharmaceuticals,Inc. Curemark LLC Rapid Micro Biosystems,Inc

2021

-10

3

GT Biopharma,Inc.

SPPI

TPG Biotechnology Partners V,L.P.　ORI Healthcare Fund,L.P.　TPG Biotechnology Partners IV,L.P.　ORI Healthcare Fund II,L.P.

SPPI

2021

SPPI

2021 12 31 RVX

RVX

4.69

2.83 RVX 1.86

0.37

RVX 2.83 0

RVX

3

2021 12 31 47,488.49 2020 12 31

61,995.25 14,506.76 23.40%

1.Aridis Pharmaceuticals,Inc. Aridis 2021 12 31

1,304.98 2020 12 31 3,479.23

2,174.25 62.49% Aridis 2020 12 31 6.07

2021 12 31 2.33

2.Cantex Pharmaceuticals,Inc Cantex 75%

Cantex 19,456.19

3.

991.08

Aridis Rapid Micro

Biosystems Inc.

1

2

4

2021 12 31

TPG Biotechnology Partners V,L.P.	
ORI Healthcare Fund,L.P.	
TPG Biotechnology Partners IV,L.P.	
GT Biopharma,Inc.	
ORI Healthcare Fund II,L.P.	

1

2

3

5

Aridis Pharmaceuticals,Inc						
		mAbs				

						Aridis FVOCI

CUREMARK
LLC, CM-AT CM-AT
III

CM-AT BLA
/

SPL CM-AT Curemark SPL Curemark

CM-AT

FDA
2

						FVOCI
Cantex Pharmaceuticals,Inc.			DSTAT AML DSTAT2019 720	1	2021	Cantex SPL DSTAT FVOCI
Rapid Micro Biosystems Inc.		Rapid Micro Biosystems RMB RMB	RMB GrowthDirect 2017 RMS GrowthDirect 20	RMB RMB		RMB GrowthDirect™ GrowthDirect™

			2021 IPO			FVOCI
Quest PharmaTech Inc.	Quest Pharma OncoQuest 2015 Quest lgG lgE Oncoquest	Quest Oncoquest Quest	2015 Oncoquest 2018 Oncoquest	1 Quest		Quest
Oncoquest Inc.		Oncoquest	Oncoquest	1		

	IgG IgE IgG Oregovomab IgE AR20.5		IgG IgE Oregovomab AR20.5			IgG IgE - First-in-Class Oncoquest 2021 Oncoquest
Resverlogix Corp.		RVX-208 MACE 1 RVX-208	RVX-208 RVX-208 BETonMACE	1		RVX-208

	RVX208	2	FDA BETonMACE2 2 FDA	A. B.		RVX RVX 2021 RVX RVX
HighTide Therapeutics,Inc.			1 12 HTD1801 A.PSC( )	1 /	HighTide	1 HighTide 2

			B. NASH+T2DM/Pre-T2DM 2 / 2 2 PSC NASH			HighTide HighTide 2019 3 HighTide 2021
			2021 12 LP	1 LP		

						3
		IPO	2021 9 13 2021 12 31 IRR 30%	1 LP		ICL) 3 2021 IPO
		3-5 IPO	C B	1 LP		2018 2019 2018 0.44 2021 1.58 259% C

			2016 12 2017 9	1 LP		
				1 LP		

			2021 12 LP LP	LP		TMT
TPG BIOTECHNOLOGY PARTNERS IV,L.P.			2021 12 TPG TPG Rapid Micro Biosystems			TPG TPG TPG

						2.5 TPG TPG

TPG
Biotechnol
ogy
Partners
V,L.P.

			LP ORI 2021 Sanofi Foreign Participations BV			3
ORI Healthcare .		/	LP			4

						ORIzon /
		3-5 IPO	10 60	1 LP		2016

						2021 6 2021

2021

2021

1.

2.

3.

4.

5.

6.

7.

8.

2021

2021

1.

2.

3.

4.

5.

6.

7.

2021

2021

56-57

6 21.52

SPL Acquisition Corp. Cytovance Biologics, Inc.

CDMO :

1

2

1

SPL Acquisition Corp SPL

CDMO

2021

2020

SPL SPL

40

55% 14

SPL

CDMO

2021

mRNA

21

8 -

2021

12 31 RVX

RVX

2.23

Hepalink USA Inc. 2014

4 9 2015 10 5 SPL 100%

2021 12 31 SPL 13.52 8.00

21.52 CDMO

KPMG LLP 2021 12 31

SPL

2

1.

/ Aridis Quest Oncoquest HighTide Resverlogix Curemark Cantex GT Biopharma,Inc. Rapid Micro Biosystems Inc.

1 Aridis Quest/Oncoquest HighTide Resverlogix

Curemark GT Biopharma,Inc. SPL Cantex Curemark SPL

2 Rapid

3

2.

/

LP

GP

GP 25%

3.

TPG Biotechnology Partners IV, L.P. TPG Biotechnology Partners V, L.P. ORI Healthcare Fund, L.P. ORI Healthcare Fund

TPG IV TPG V ORI

ORI Kymab

Kymab

5 5

2021

5

2021

2021

1.

2.

3.

4. EBITDA EBITDA

5.

6. /

7.

8.

9.

2021

2021

63

7 **1.02** **2.58**

2.41 **0.9**

2022 **7.6.6**

10%

2021

2021

2021 4 11

4 12 2021 4 14

8 24.49 15.12

2.52

5,224.5

1

2

3

7

3

1

1

2

a

b

2

1

	Curemark LLC		http://static.cninfo.com.cn/finalpage/2018-01-06/1204309442.PDF	
	TPG Biotechnology Partners V,L.P.		http://static.cninfo.com.cn/finalpage/2016-06-17/1202371510.PDF	
	ORI Healthcare Fund,L.P.	1 2	http://static.cninfo.com.cn/finalpage/2016-01-23/1201935573.PDF http://static.cninfo.com.cn/finalpage/2016-09-21/1202710289.PDF	
	ORI Healthcare Fund ,L.P.		http://static.cninfo.com.cn/finalpage/2020-10-24/1208608152.PDF	
	RVX			
			http://static.cninfo.com.cn/finalpage/2015-10-12/1201680945.PDF	

	TPG Biotechnology Partners IV,L.P.		http://static.cninfo.com.cn/finalpage/2014-11-04/1200366486.PDF	

2

	Resverlogix Corp	2017 6 20	2021 6 20			
	Resverlogix Corp	2017 12 5	2021 12 5		http://static.cninfo.com.cn/finalpage/2017-10-14/1204040105.PDF	
	Resverlogix Corp	2019 1 31	2022 1 31			
	Resverlogix Corp	2019 3 29	2022 3 29			
	Resverlogix Corp	2020 8 14	2021 8 14			
	Resverlogix Corp	2021 5 13	2025 5 13			

3

7

1 2.52

Curemark LLC Curemark

2018 1 15

SPL Curemark

500 Curemark 14,429

2018 1 15 200 2018

2 28 300 SPL 5,453.80

DMF Curemark

Curemark 157,388

Curemark Curemark

5,953.80 37,608.96

2016 79.71 30% 2015 4

2015 4

2018-002 2018 1 6

2021

2020 2020 3 30

SPL Curemark SPL Curemark Curemark

1,252 7,983.17

2018 60.68 5% 2020

2 2015 4 SPL

2021 Curemark

ORI Healthcare Fund,L.P.

2016 1 22

2,000 13,105.4

ORI Healthcare Fund,L.P. I

I

2014 82.70

5% 2015 4 2015 4

2016-004 2016

1 23

2016 9 20 I

I

2,000 13,343

2015

87.19 5% 2015 4

2015 4

ORI Healthcare Fund,L.P. 2016-068

2016 9 21

2021

2021 I 424.92

ORI Healthcare Fund ,L.P.

2020 10 23

4,000 26,844.4

ORI Healthcare Fund ,L.P.

2021

2021 TPG V 656.61

TPG Biotechnology Partners IV,L.P.

2014 11 3 TPG Biotechnology Partners IV,L.P. TPG IV 17,358,389 TPG Holdings I,L.P. TPG Holdings II,L.P. TPG 500 , 11,569.74

2013 79.86 5% 2014 4 2011 2

TPG BIOTECHNOLOGY PARTNERS IV,L.P.

2014-075

2021

2021 TPG IV 95.67

RVX

2021 4 22 RVX 600 RVX 2020 190.26 10% 2020 7 2019 12 H

2015 3 18

1,000

2.5

2013 79.86

5% 2014 4 2011 2

2015-013

2015 10 10

2000

2014 82.7 5% 2015 4

2015 4

2015-088

2 5,224.50

70.53

RVX

RVX RVX

2021 12 31 RVX

2017 6 20	- RVX13,270,000 1.80 / 1,333,333 - 2015 4 2015

2.

3.

4.

5.

6.

7.

8.

9.

2021

2021

74

Curemark LLC

2020 2 2020 2

2015 4 Curemark

TPG Biotechnology Partners V,L.P.

2015 4 2015 4

2015 4 TPG BIOTECHNOLOGY PARTNERS V, L.P.

ORI HealthcareFund,L.P.

2015 4 2015 4

2015 4 ORI HealthcareFund,L.P.

2014 4 2011 1

2011 2

ORI HealthcareFund ,L.P.

2020 7 2020 6 H

2019 12 H

RVX

2020 7 2020 6 H

2019 12 H

2021

TPG Biotechnology Partners IV,L.P.

2014 4 2011 1

2011 2

RVX

RVX Resverlogix

Corp. 2021 12 31

Resverlogix Corp.

2021

7

9 2021 2.44 32.39%

0.63 0.74 0.41 0.31

1

–

2

3 0.46

0.58

4 -

1

-

	6,313.21
	7,358.22
	4,084.21
	5,335.20
	2,764.59
	104.79
	3,058.49
	29,018.72

6,313.21

1 Sanofi Aventis 4,035.06 2021 1

Sanofi Kymab Group Limited

Sanofi 1.17 2021 632.88

2022

2 TPG Biotechnology Partners IV, L.P. 1,543.31

2022 7,358.22

1 3,753.44

2022

300

2 Abbvie1,782.51 SPL2016

Abbvie SPL Abbvie

AbbVie SPL SPL

SPL Abbvie 3%

FDA 2020 12 31

Abbvie SPL

3 1,330.03

4,084.21

1 RVX4,084.21 RVX RVX-208

2020 6 RVX-208 BETonMACE2 FDA

5,335.20 5,335.20

-

	2021 12 31	2020 12 31
	1,283	-
	651	-
	619	975
	215	117
	75	280
	-	672
	215	272
	3,058	2,316

–

–

2

RVX RVX

RVX

3 0.46

0.58

2021 12 31

	3			
	a	b	a-b	b/a
	4,084	-	4,084	-
	1,335	1,055	280	79%
	351	236	115	67%
	56	46	10	83%
	5,826	1,337	4,490	23%

2021 12 31 0.58

1 4,084 RVX

RVX RVX-208 RVX-208

2020 6 RVX-208BETonMACE2 FDA

2 1,335

2021 12 31 0.46

	2,810
	1,828
	4,638

12

2021 12 31

0.28 0.18 0.46

0.13

4 –

–

	2021 12 31	2020 12 31
	1,725.53	46.09
	1,355.20	1,270.78
	1,181.87	404.96
	284.66	167.13
	537.36	474.65
	187.71	131.89
	1,770.75	2,431.35
	7,043.08	4,926.85

2021

2021

1.

2.

3.

4.

5.

2021

2021

82

10 1.98

1

2 5%

1

		%	
A	3,580.47	18.06%	
	3,180.00	16.04%	
B	1,879.08	9.48%	
C	800.00	4.04%	
D	709.55	3.58%	
	10,149.10	51.20%	

1

A B C D

A B C

D

2021

2021

1.

2.

3.

4.

5.

6.

2021

2021

85